Brought to you by 
Lin BioScience licenses CDC7 kinase inhibitor from Columbia Univ., Memorial Sloan Kettering
28 Apr 2017
Executive Summary
Columbia University and Memorial Sloan Kettering Cancer Center granted Lin BioScience Inc. exclusive global rights to IP surrounding a novel CDC7 kinase inhibitor, which Lin will develop as LBS007 for solid and blood cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lin BioScience licenses CDC7 kinase inhibitor from Columbia Univ., Memorial Sloan Kettering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice